Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?

Key Takeaways NVO leans on GLP-1 leadership, with Ozempic, Wegovy and Rybelsus driving growth but facing rising competition.AMGN benefits from diversification, with oncology, rare disease, biosimilars, and obesity studies underway.NVO shares fell sharply over six months, while AMGN stock gained as earnings estimates trended higher.Both Novo Nordisk (NVO) and Amgen (AMGN) are large-cap, innovation-driven healthcare leaders with global scale, strong balance sheets, and a track record of turning scientific bre ...